<DOC>
	<DOCNO>NCT00783380</DOCNO>
	<brief_summary>Evaluation immunogenicity reactogenicity two different formulation commercially avail-able influenza vaccine 4 different group immunocompromized outpatient ( HIV positive patient , patient suffer rheumatologic disease receive treatment immunosuppressive drug patient undergo hemodialysis continuous ambulatory peritoneal dialysis ) . The aim study investigate new formulation influenza vaccine ( virosomal vaccine ) offer benefit immunocompromized patient comparison old subunit formulation .</brief_summary>
	<brief_title>Influenza Vaccination Immunocompromized Patients</brief_title>
	<detailed_description>The infection influenza associate high morbidity mortality risk group include immunocompromized patient . The virosomal influenza vaccine associate improved immunogenicity former trial . No direct comparison old formulation conduct far .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult outpatient treat Inselspital Bern : HIV infection rheumatologic diseases receive immunosuppressive drug kidney transplant recipient undergoing hemodialysis continuous ambulatory peritoneal dialysis write informed consent Allergy egg protein Former adverse reaction prior vaccination Febrile condition time study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Influenza vaccination</keyword>
	<keyword>Subunit</keyword>
	<keyword>Virosomal</keyword>
	<keyword>HIV/AIDS</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Rheumatologic disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Reactogenicity</keyword>
</DOC>